论文部分内容阅读
目的观察思力华联合舒利迭治疗稳定期中重度慢性阻塞性肺疾病(COPD)的效果。方法确诊稳定期中重度COPD患者40例随机均分为两组,常规止咳平喘治疗基础上,A组加用思力华和舒利迭治疗:思力华每日1次,每次1吸;舒利迭每日2次,每次1吸。B组仅加用舒利迭。记录治疗前、治疗1个月和3个月时的圣乔治问卷调查表(SGRQ)评分;测定治疗前和治疗3个月后血清IL-32浓度。结果两组治疗后的SGRQ评分均较治疗前减少(P<0.01)。A组和B组治疗3个月后的血清IL-32表达均比治疗前降低[(60.5±13.5)ng/L vs.(70.2±13.5)ng/L和(61.3±12.5)ng/L vs.(70.5±14.1)ng/L](P<0.05)。两组治疗期间均未见明显不良反应。结论在常规止咳平喘治疗基础上,应用舒利迭或思力华和舒利迭联用均能改善稳定期中重度COPD患者的临床症状和生活质量,降低患者血清IL-32表达水平。
Objective To observe the effect of silivin combined with seretide on stable chronic obstructive pulmonary disease (COPD). Methods Forty patients with moderate-to-severe COPD diagnosed as stable were randomly divided into two groups. On the basis of routine cough-and-asthma treatment, group A was treated with silivin and seretide: Seretide 2 times a day, each suction. B group only with Seretide. The St. George’s Questionnaire (SGRQ) score was recorded before treatment, at 1 month and at 3 months. Serum IL-32 levels were measured before and 3 months after treatment. Results After treatment, the SGRQ scores of both groups decreased compared with before treatment (P <0.01). The levels of IL-32 in serum of group A and group B after 3 months treatment were lower than those before treatment [(60.5 ± 13.5) ng / L vs. (70.2 ± 13.5) ng / L vs (61.3 ± 12.5) ng / L vs (70.5 ± 14.1) ng / L] (P <0.05). No significant adverse reactions were observed during the two groups. Conclusion On the basis of routine cough and asthma treatment, the combination of seretide or siliver and seretide can improve the clinical symptoms and quality of life in patients with moderate-to-severe COPD and decrease the serum IL-32 level.